The Superior Court of California for the District of Los Angeles has granted Byetta plaintiffs’ motion to unseal images from a 273-day monkey study conducted by Amylin Pharmaceuticals, a subsidiary of AstraZeneca. According to a court document, the ruling was made at a July 9 status conference.
Byetta is a widely prescribed type 2 diabetes medication belonging to the incretin mimetic class of drugs. Despite its popularity, Byetta has been the ...
continue reading...